Synopsis
Synopsis
0
JDMF
0
EU WC
0
VMF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Methylglucamine
1. N-methyl-d-glucamine
2. 6284-40-8
3. N-methylglucamine
4. Meglumin
5. 1-deoxy-1-(methylamino)-d-glucitol
6. Methylglucamin
7. N-methylsorbitylamine
8. D-glucitol, 1-deoxy-1-(methylamino)-
9. Methylglucamine
10. Meglumina
11. Megluminum
12. 1-deoxy-1-methylaminosorbitol
13. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol
14. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol
15. N-methyl-d(-)-glucamine
16. Megluminum [inn-latin]
17. Meglumina [inn-spanish]
18. Sorbitol, 1-deoxy-1-methylamino-
19. Unii-6hg8ub2muy
20. D(-)-n-methylglucamine
21. 6hg8ub2muy
22. Chebi:59732
23. Nsc-7391
24. Nsc-52907
25. Nsc 7391
26. Nsc 52907
27. Dsstox_cid_3244
28. Dsstox_rid_76939
29. Dsstox_gsid_23244
30. Glucitol, 1-deoxy-1-(methylamino)-, D-
31. Einecs 228-506-9
32. N-methylglucamine Solution
33. Nsc52907
34. Meglumine [usp:inn:ban:jan]
35. N-methyl-glucamine
36. N-methyl Glucamine
37. Ncgc00166125-01
38. Cas-6284-40-8
39. Mfcd00004707
40. Meglumine [inn]
41. Meglumine [jan]
42. Meglumine [ii]
43. N-methylglucamine Solution (70% Or Less)
44. Meglumine [vandf]
45. Meglumine [mart.]
46. Ec 228-506-9
47. Meglumine [usp-rs]
48. Meglumine [who-dd]
49. Meglumine [who-ip]
50. Schembl2193
51. Bidd:gt0676
52. Methylglucamine [inci]
53. Meglumine (jp17/usp/inn)
54. N-methylglucamine [mi]
55. Meglumine [orange Book]
56. Chembl1200570
57. Dtxsid0023244
58. Meglumine [ep Monograph]
59. Meglumine [usp Monograph]
60. Megluminum [who-ip Latin]
61. 1-deoxy-1-(methylamino)-glucitol
62. 1-methylamino-1-deoxy-d-glucitol
63. Hms2089b05
64. Hms3714b10
65. Pharmakon1600-01300029
66. Hy-b0342
67. Zinc2020259
68. Tox21_112330
69. Tox21_302037
70. Nsc759607
71. S1974
72. Akos005167162
73. Akos015850890
74. N-methyl-1-amino-1-deoxy-d-glucitol
75. Tox21_112330_1
76. Ac-4692
77. Ccg-220884
78. Nsc-759607
79. Meglumine 100 Microg/ml In Acetonitrile
80. Ncgc00166125-02
81. Ncgc00255365-01
82. Ac-17087
83. As-12002
84. Sbi-0206683.p002
85. Meglumine, Meets Usp Testing Specifications
86. Am20100540
87. M0227
88. Sw199350-2
89. D01796
90. Ab00430469-03
91. Ab00430469_05
92. A834035
93. Q288875
94. Sr-05000001446
95. N-methyl-d-glucamine, 99.0-100.5% (titration)
96. Sr-05000001446-1
97. Brd-k28595280-001-01-1
98. N-methyl-d-glucamine, Vetec(tm) Reagent Grade, 99%
99. Wurcs=2.0/1,1,0/[h2122h_1*nc]/1/
100. N-methyl-d-glucamine, Reagentplus(r), >=99.0% (t)
101. (2r,3r,4r,5s)-6-methylamino-hexane-1,2,3,4,5-pentaol
102. Meglumine, United States Pharmacopeia (usp) Reference Standard
103. N-methyl-(2 (s),3 (r),4 (r),5 (r),6-pentahydroxy-hexyl)-amine
104. Meglumine, Pharmaceutical Secondary Standard; Certified Reference Material
105. N-methyl-d-glucamine, European Pharmacopoeia (ep) Reference Standard
| Molecular Weight | 195.21 g/mol |
|---|---|
| Molecular Formula | C7H17NO5 |
| XLogP3 | -2.8 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 195.11067264 g/mol |
| Monoisotopic Mass | 195.11067264 g/mol |
| Topological Polar Surface Area | 113 Ų |
| Heavy Atom Count | 13 |
| Formal Charge | 0 |
| Complexity | 134 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Contrast Media
Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
35
PharmaCompass offers a list of Meglumine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Meglumine manufacturer or Meglumine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Meglumine manufacturer or Meglumine supplier.
PharmaCompass also assists you with knowing the Meglumine API Price utilized in the formulation of products. Meglumine API Price is not always fixed or binding as the Meglumine Price is obtained through a variety of data sources. The Meglumine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Meglumine Ioxitalamate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Meglumine Ioxitalamate, including repackagers and relabelers. The FDA regulates Meglumine Ioxitalamate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Meglumine Ioxitalamate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Meglumine Ioxitalamate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Meglumine Ioxitalamate supplier is an individual or a company that provides Meglumine Ioxitalamate active pharmaceutical ingredient (API) or Meglumine Ioxitalamate finished formulations upon request. The Meglumine Ioxitalamate suppliers may include Meglumine Ioxitalamate API manufacturers, exporters, distributors and traders.
click here to find a list of Meglumine Ioxitalamate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Meglumine Ioxitalamate DMF (Drug Master File) is a document detailing the whole manufacturing process of Meglumine Ioxitalamate active pharmaceutical ingredient (API) in detail. Different forms of Meglumine Ioxitalamate DMFs exist exist since differing nations have different regulations, such as Meglumine Ioxitalamate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Meglumine Ioxitalamate DMF submitted to regulatory agencies in the US is known as a USDMF. Meglumine Ioxitalamate USDMF includes data on Meglumine Ioxitalamate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Meglumine Ioxitalamate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Meglumine Ioxitalamate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Meglumine Ioxitalamate Drug Master File in Korea (Meglumine Ioxitalamate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Meglumine Ioxitalamate. The MFDS reviews the Meglumine Ioxitalamate KDMF as part of the drug registration process and uses the information provided in the Meglumine Ioxitalamate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Meglumine Ioxitalamate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Meglumine Ioxitalamate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Meglumine Ioxitalamate suppliers with KDMF on PharmaCompass.
A Meglumine Ioxitalamate CEP of the European Pharmacopoeia monograph is often referred to as a Meglumine Ioxitalamate Certificate of Suitability (COS). The purpose of a Meglumine Ioxitalamate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Meglumine Ioxitalamate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Meglumine Ioxitalamate to their clients by showing that a Meglumine Ioxitalamate CEP has been issued for it. The manufacturer submits a Meglumine Ioxitalamate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Meglumine Ioxitalamate CEP holder for the record. Additionally, the data presented in the Meglumine Ioxitalamate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Meglumine Ioxitalamate DMF.
A Meglumine Ioxitalamate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Meglumine Ioxitalamate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Meglumine Ioxitalamate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Meglumine Ioxitalamate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Meglumine Ioxitalamate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Meglumine Ioxitalamate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Meglumine Ioxitalamate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Meglumine Ioxitalamate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Meglumine Ioxitalamate suppliers with NDC on PharmaCompass.
Meglumine Ioxitalamate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Meglumine Ioxitalamate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Meglumine Ioxitalamate GMP manufacturer or Meglumine Ioxitalamate GMP API supplier for your needs.
A Meglumine Ioxitalamate CoA (Certificate of Analysis) is a formal document that attests to Meglumine Ioxitalamate's compliance with Meglumine Ioxitalamate specifications and serves as a tool for batch-level quality control.
Meglumine Ioxitalamate CoA mostly includes findings from lab analyses of a specific batch. For each Meglumine Ioxitalamate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Meglumine Ioxitalamate may be tested according to a variety of international standards, such as European Pharmacopoeia (Meglumine Ioxitalamate EP), Meglumine Ioxitalamate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Meglumine Ioxitalamate USP).
